Pfizer

PFE Large Cap

Healthcare · Drug Manufacturers - General

Updated: Apr 5, 2026, 00:03 UTC

$28.32

-0.81% today

52W: $20.92 – $28.75

52W Low: $20.92 Position: 94.5% 52W High: $28.75

🔗 Compare Brokers Best Broker for Beginners →

Key Metrics

P/E Ratio

20.82x

Price-to-Earnings

Forward P/E

10.03x

Forward Price/Earnings

P/S Ratio

2.57x

Price-to-Sales

EV/EBITDA

8.38x

Enterprise Value/EBITDA

Div. Yield

607%

Annual dividend yield

Market Cap

$161.1B

Market Capitalization

Revenue Growth

-1.2%

YoY Revenue Growth

Profit Margin

12.42%

Net profit margin

ROE

8.89%

Return on Equity

Beta

0.39

Market sensitivity

Short Interest

2.31%

% of float sold short

Avg. Volume

45,932,866

Average daily volume

Valuation Analysis

Signal

Fair

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Buy

26 analysts

Avg. Price Target

$28.58

+0.92% upside

Target Range

$25.00 – $36.00

★ Smart Money Investors

♣ Burry

This stock is held by one or more of our 15 tracked Smart Money managers. Click a name to view their full portfolio.

About the Company

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Geno

Sector: Healthcare Industry: Drug Manufacturers - General Country: United States Employees: 75,000 Exchange: NYQ